INGN - NASDAQ
Inogen, Inc.
$5.98
-1.6%Inogen, Inc., a medical technology company, develops, manufactures, and markets portable oxygen concentrators to patients, physicians and other clinicians, and third-party payors in the United States and internationally. Its oxygen concentrators are used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions. The company offers Inogen One, a portable device that concentrate the air around the patient to provide a single source of supplemental oxygen; Inogen At Home stationary oxygen concentrators; Inogen Tidal Assist Ventilators, as well as related accessories. The company also rents its products directly to patients. Inogen, Inc. was incorporated in 2001 and is headquartered in Goleta, California.
At a Glance
Live SnapshotInogen, Inc. Management Team
Ms. Ryan Peterson
Associate Director of Investor Relations
Dr. Krishna Jhaveri
Chief Medical Officer
Mr. Grgoire Ramade
Executive Vice President & Chief Commercial Officer
Compensation
$874,118
Ms. Jennifer Yi Boyer
Executive Vice President & Chief Human Resources Officer
Mr. Michael J. Bourque CPA
Executive Vice President, Chief Financial Officer & Corporate Treasurer
Compensation
$885,923
Mr. Kevin P. Smith
General Counsel, Secretary & Executive Vice President of Business Development
Compensation
$478,000
Mr. Kevin R. M. Smith
President, Chief Executive Officer & Director
Compensation
$2,972,754
Mr. Philip Corrin
Senior Vice President of Operations & Supply Chain
Mr. Paul Andreassi
Senior Vice President of Quality & Regulatory Affairs
Mr. Adrien Mithalal
Senior Vice President of Research & Development
Inogen, Inc. Insider Positioning
During the last 12 months, insiders have purchased $36K and sold $70K worth of INGN shares, resulting in $34K of net selling activity.
3 Months
0
0.00
10.8K
70.31K
-70K
-$70K
3-6 Months
0
0.00
0
0.00
+0
+$0
6-9 Months
0
0.00
0
0.00
+0
+$0
9-12 Months
4.5K
35.95K
0
0.00
+36K
+$36K
Top Buyers
Bourque Michael J.
Officer: Evp, Cfo & Treasurer
$12K
Smith Kevin P.
Officer: Evp, Bus Dev, Gc & Sec
$12K
Smith Kevin Raymond Merrill
Director, Officer: Ceo And President
$12K
Top Sellers
Yi Boyer Jennifer M
Officer: Evp Entrprs Enblmnt, Ch Hr Off
$70K
Insider Activity Analysis
Net Insider Sentiment
Slightly bearish with $34K net selling. Selling modestly exceeds buying, which could be routine diversification rather than concern.
Buy/Sell Ratio
Moderately negative ratio. Selling is roughly double the buying, which may be routine or signal caution.
Recent Trend (3 Months)
Heavy recent selling activity. Recent insider sales notably exceed purchases—may warrant investigation into company developments.
Insider Participation
3 insider buyers vs. 1 sellers. Broad-based buying across management team suggests widespread confidence.
SEC Filings
INGN - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
DEF 14A DEF 14A 2026 N/A | April 28, 2026 | April 28, 2026 | 2026 | |
DEF 14A DEF 14A 2025 N/A | March 27, 2025 | March 27, 2025 | 2025 | |
DEF 14A DEF 14A 2024 N/A | April 18, 2024 | June 05, 2024 | 2024 | |
DEF 14A DEF 14A N/A | April 18, 2023 | April 18, 2023 | ||
DEF 14A DEF 14A 2022 N/A | April 21, 2022 | June 08, 2022 | 2022 | |
DEF 14A DEF 14A 2021 N/A | March 23, 2021 | May 10, 2021 | 2021 | |
DEF 14A DEF 14A 2020 N/A | March 24, 2020 | May 07, 2020 | 2020 | |
DEF 14A DEF 14A 2019 N/A | March 26, 2019 | May 09, 2019 | 2019 | |
DEF 14A DEF 14A 2018 N/A | March 27, 2018 | May 10, 2018 | 2018 | |
DEF 14A DEF 14A 2017 N/A | March 28, 2017 | May 11, 2017 | 2017 |
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.